Company intelligence / Profile preview

Shanghai Xunbaihui Biotechnology

Shanghai, Shanghai, China

Ownership: Private
Development stage: Other

Overview

Shanghai Xunbaihui Biotechnology is a Chinese biopharmaceutical company focused on the development of innovative cell therapies for the treatment of cancer. The company specializes in Natural Killer (NK) cell-based technologies, aiming to overcome the limitations of current immunotherapies in treating solid tumors. Their research focuses on enhancing the persistence and tumor-killing efficacy of NK cells through genetic engineering and optimized culture systems. Xunbaihui is currently advancing a pipeline of pre-clinical candidates targeting various oncological indications.

Therapeutic areas: Oncology
Modalities: Cell therapyBiologicNK cell therapy
Industry: Biotech

Beyond the preview

Go deeper on Shanghai Xunbaihui Biotechnology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Shanghai Xunbaihui Biotechnology.

Explore the full profile